PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29915281-9 2018 In mouse xenograft models, combining PDGFR-alpha/beta inhibition (using shRNA or imatinib) with doxorubicin had a more-than-additive effect in blocking tumor growth, with enhanced apoptosis, especially in CD133(+) cells. Imatinib Mesylate 81-89 platelet derived growth factor receptor, alpha polypeptide Mus musculus 37-48 31428517-10 2019 Analysis of the Gene Expression Omnibus database GIST samples pre- and post-treatment confirmed that imatinib downregulates PD-L1 and IRF1 expression through the inhibition of KIT and PDGFRA, thus contributing to counteract the suppressed adaptive immune response against GIST. Imatinib Mesylate 101-109 platelet derived growth factor receptor, alpha polypeptide Mus musculus 184-190 25865047-12 2015 PDGFRA knockdown or inhibition with crenolanib efficiently reduced proliferation of imatinib-sensitive and imatinib-resistant KIT(+)ETV1(+)PDGFRA(+) GIST cells (50% maximal inhibitory concentration = 5-32 nM), but not of cells lacking KIT, ETV1, or PDGFRA (50% maximal inhibitory concentration >230 nM). Imatinib Mesylate 107-115 platelet derived growth factor receptor, alpha polypeptide Mus musculus 0-6 30007969-0 2018 Imatinib Ameliorated Retinal Neovascularization by Suppressing PDGFR-alpha and PDGFR-beta. Imatinib Mesylate 0-8 platelet derived growth factor receptor, alpha polypeptide Mus musculus 63-74 30007969-2 2018 Here we evaluated the anti-angiogenic effect of imatinib, an inhibitor of PDGF receptors alpha and beta (PDGFR-alpha and -beta), in retinal neovascularization using an oxygen-induced retinopathy (OIR) model. Imatinib Mesylate 48-56 platelet derived growth factor receptor, alpha polypeptide Mus musculus 105-126 26500491-4 2015 In this study we examine the efficacy for the treatment of TBI of an FDA approved antagonist of the PDGFRalpha, Imatinib. Imatinib Mesylate 112-120 platelet derived growth factor receptor, alpha polypeptide Mus musculus 100-110 29570794-5 2018 Conditional deletion of the platelet-derived growth factor (PDGF) receptor-alpha (PDGFRA) gene (Pdgfra) and inhibition of PDGFRA by imatinib in leptin receptor+ stromal cells suppressed their expansion and ameliorated bone marrow fibrosis. Imatinib Mesylate 132-140 platelet derived growth factor receptor, alpha polypeptide Mus musculus 122-128 30007969-7 2018 Moreover, the expression and activation of PDGFR-alpha and -beta were inhibited by imatinib. Imatinib Mesylate 83-91 platelet derived growth factor receptor, alpha polypeptide Mus musculus 43-64 28139720-6 2017 Using this model, we found that platelet-derived growth factor receptor-alpha (PDGFRalpha)-positive mesenchymal stem cells are induced after this intervention and that inhibition of PDGFR signaling by imatinib treatment can significantly suppress fatty infiltration. Imatinib Mesylate 201-209 platelet derived growth factor receptor, alpha polypeptide Mus musculus 32-77 28139720-6 2017 Using this model, we found that platelet-derived growth factor receptor-alpha (PDGFRalpha)-positive mesenchymal stem cells are induced after this intervention and that inhibition of PDGFR signaling by imatinib treatment can significantly suppress fatty infiltration. Imatinib Mesylate 201-209 platelet derived growth factor receptor, alpha polypeptide Mus musculus 79-89 25865047-12 2015 PDGFRA knockdown or inhibition with crenolanib efficiently reduced proliferation of imatinib-sensitive and imatinib-resistant KIT(+)ETV1(+)PDGFRA(+) GIST cells (50% maximal inhibitory concentration = 5-32 nM), but not of cells lacking KIT, ETV1, or PDGFRA (50% maximal inhibitory concentration >230 nM). Imatinib Mesylate 84-92 platelet derived growth factor receptor, alpha polypeptide Mus musculus 0-6 24486648-8 2014 In contrast, ponatinib efficiently eradicated leukemic cells expressing Hes1 and the imatinib-resistant FLP1L1-PDGFRAlpha mutant in vitro and in vivo. Imatinib Mesylate 85-93 platelet derived growth factor receptor, alpha polypeptide Mus musculus 111-121 24486648-7 2014 Imatinib inhibited the growth of common myeloid progenitors expressing Hes1 with FIP1L1-PDGFRalpha, but not with imatinib-resistant FIP1L1-PDGFRalpha mutants harboring T674I or D842V. Imatinib Mesylate 0-8 platelet derived growth factor receptor, alpha polypeptide Mus musculus 88-98 24599309-11 2014 A phospho-receptor tyrosine kinase array kit revealed that PDGFRalpha, among 7 other receptors (PDFGFRbeta, Axl, RYK, EGFR, EphA2 and 10, IGF1R), appears as one of the main molecular targets for imatinib mesylate. Imatinib Mesylate 195-203 platelet derived growth factor receptor, alpha polypeptide Mus musculus 59-69 24407160-11 2014 We also examined drug effects on Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V. Imatinib Mesylate 81-89 platelet derived growth factor receptor, alpha polypeptide Mus musculus 124-130 20518073-1 2010 In previous in vitro studies, we showed that imatinib abrogated platelet-derived growth factor receptor alpha (PDGFRalpha) signaling, disrupting both breast cancer and smooth muscle cells (SMC). Imatinib Mesylate 45-53 platelet derived growth factor receptor, alpha polypeptide Mus musculus 64-109 22745105-0 2012 Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Imatinib Mesylate 77-85 platelet derived growth factor receptor, alpha polypeptide Mus musculus 39-45 22745105-4 2012 RESULTS: Crenolanib was significantly more potent than imatinib in inhibiting the kinase activity of imatinib-resistant PDGFRA kinases (D842I, D842V, D842Y, DI842-843IM, and deletion I843). Imatinib Mesylate 55-63 platelet derived growth factor receptor, alpha polypeptide Mus musculus 120-126 22745105-4 2012 RESULTS: Crenolanib was significantly more potent than imatinib in inhibiting the kinase activity of imatinib-resistant PDGFRA kinases (D842I, D842V, D842Y, DI842-843IM, and deletion I843). Imatinib Mesylate 101-109 platelet derived growth factor receptor, alpha polypeptide Mus musculus 120-126 22745105-9 2012 CONCLUSIONS: Crenolanib is a potent inhibitor of imatinib-resistant PDGFRA kinases associated with GIST, including the PDGFRA D842V mutation found in approximately 5% of GISTs. Imatinib Mesylate 49-57 platelet derived growth factor receptor, alpha polypeptide Mus musculus 68-74 24009732-0 2013 The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRalpha. Imatinib Mesylate 83-91 platelet derived growth factor receptor, alpha polypeptide Mus musculus 132-142 24009732-1 2013 The cells expressing the T674I point mutant of FIP1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRalpha) in hypereosinophilics syndrome (HES) are resistant to imatinib and some second-generation tyrosine kinase inhibitors (TKIs). Imatinib Mesylate 179-187 platelet derived growth factor receptor, alpha polypeptide Mus musculus 113-123 23041331-9 2013 RESULTS: Loss of Ptch from lysozyme M-expressing cells resulted in the development of tumors of GIST-like localization and histology; these were reduced when mice were given imatinib, a drug that targets KIT and PDGFRA. Imatinib Mesylate 174-182 platelet derived growth factor receptor, alpha polypeptide Mus musculus 212-218 22447844-1 2012 PURPOSE: The "gate-keeper" mutations T674I platelet-derived growth factor receptor alpha (PDGFRalpha) in hypereosinophilic syndrome (HES) and T315I Bcr-Abl in chronic myeloid leukemia (CML) are resistant to imatinib and the second-generation small-molecule tyrosine kinase inhibitors (TKI). Imatinib Mesylate 207-215 platelet derived growth factor receptor, alpha polypeptide Mus musculus 90-100 20518073-1 2010 In previous in vitro studies, we showed that imatinib abrogated platelet-derived growth factor receptor alpha (PDGFRalpha) signaling, disrupting both breast cancer and smooth muscle cells (SMC). Imatinib Mesylate 45-53 platelet derived growth factor receptor, alpha polypeptide Mus musculus 111-121 20518073-10 2010 Imatinib further inhibited PDGFRalpha expression and activity, as confirmed by the down-regulation of downstream Erk signaling pathway. Imatinib Mesylate 0-8 platelet derived growth factor receptor, alpha polypeptide Mus musculus 27-37 20621681-2 2010 Kit/Pdgfra inhibitors such as imatinib mesylate have increased progression-free survival in metastatic GIST but are not curative. Imatinib Mesylate 30-47 platelet derived growth factor receptor, alpha polypeptide Mus musculus 4-10 20523072-3 2010 FIP1L1/PDGFR alpha-positive disorders are characterized by clonal hypereosinophilia, multiple organ dysfunctions due to eosinophil infiltration, systemic mastocytosis (SM) and a dramatic response to treatment with imatinib mesylate. Imatinib Mesylate 214-231 platelet derived growth factor receptor, alpha polypeptide Mus musculus 7-18 17999742-8 2007 In summary, the small molecule inhibitor imatinib attenuates stromal cell proliferation in PDGF-C-induced HCC, which coincides with decreased expression of both CD34 and PDGFRalpha, and activated Akt. Imatinib Mesylate 41-49 platelet derived growth factor receptor, alpha polypeptide Mus musculus 170-180 18568034-5 2008 These effects are mediated through activation of PDGF-alpha receptors (PDGFR-alpha) on perivascular astrocytes, and treatment of mice with the PDGFR-alpha antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. Imatinib Mesylate 166-174 platelet derived growth factor receptor, alpha polypeptide Mus musculus 71-82 18568034-5 2008 These effects are mediated through activation of PDGF-alpha receptors (PDGFR-alpha) on perivascular astrocytes, and treatment of mice with the PDGFR-alpha antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. Imatinib Mesylate 166-174 platelet derived growth factor receptor, alpha polypeptide Mus musculus 143-154 12429650-7 2002 STI571 (1.0 micro M) inhibited both PDGFR-alpha and PDGFR-beta phosphorylation and the downstream phosphorylation targets extracellular signal-regulated kinase and Akt. Imatinib Mesylate 0-6 platelet derived growth factor receptor, alpha polypeptide Mus musculus 36-47 15928335-0 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. Imatinib Mesylate 101-109 platelet derived growth factor receptor, alpha polypeptide Mus musculus 0-6 15928335-2 2005 A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro. Imatinib Mesylate 183-191 platelet derived growth factor receptor, alpha polypeptide Mus musculus 72-117 15928335-2 2005 A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro. Imatinib Mesylate 183-191 platelet derived growth factor receptor, alpha polypeptide Mus musculus 119-125 15928335-10 2005 CONCLUSION: Including our cases, there are 289 reported PDGFRA-mutant GISTs, of which 181 (62.6%) had the imatinib-resistant substitution D842V. Imatinib Mesylate 106-114 platelet derived growth factor receptor, alpha polypeptide Mus musculus 56-62 15928335-11 2005 However, our findings suggest that more than one third of GISTs with PDGFRA mutations may respond to imatinib and that mutation screening may be helpful in the management of these tumors. Imatinib Mesylate 101-109 platelet derived growth factor receptor, alpha polypeptide Mus musculus 69-75 15221957-0 2004 Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. Imatinib Mesylate 31-39 platelet derived growth factor receptor, alpha polypeptide Mus musculus 170-215 15221957-4 2004 In the present study, we examined the effect of imatinib on autophosphorylation of mutant PDGFRA, phosphorylation of MAPK and of Akt and in vitro cell proliferation using murine Ba/F3 cells stably transfected with one of the 2 murine-type mutated PDGFRA cDNAs. Imatinib Mesylate 48-56 platelet derived growth factor receptor, alpha polypeptide Mus musculus 90-96 15221957-5 2004 Imatinib almost completely inhibited autophosphorylation of mutant PDGFRA, phosphorylation of MAPK and Akt as well as in vitro cell proliferation at the concentration of 0.01 microM in cells expressing mutant PDGFRA with Val561 to Asp. Imatinib Mesylate 0-8 platelet derived growth factor receptor, alpha polypeptide Mus musculus 67-73 15221957-5 2004 Imatinib almost completely inhibited autophosphorylation of mutant PDGFRA, phosphorylation of MAPK and Akt as well as in vitro cell proliferation at the concentration of 0.01 microM in cells expressing mutant PDGFRA with Val561 to Asp. Imatinib Mesylate 0-8 platelet derived growth factor receptor, alpha polypeptide Mus musculus 209-215 15221957-6 2004 However, in cells expressing mutant PDGFRA with Asp842 to Val, imatinib almost completely inhibited autophosphorylation of mutant PDGFRA and phosphorylation of MAPK and Akt at 1.0 microM. Imatinib Mesylate 63-71 platelet derived growth factor receptor, alpha polypeptide Mus musculus 36-42 15221957-6 2004 However, in cells expressing mutant PDGFRA with Asp842 to Val, imatinib almost completely inhibited autophosphorylation of mutant PDGFRA and phosphorylation of MAPK and Akt at 1.0 microM. Imatinib Mesylate 63-71 platelet derived growth factor receptor, alpha polypeptide Mus musculus 130-136 15221957-8 2004 Ba/F3 cells expressing mutant PDGFRA are a good model to investigate the mechanism of cell proliferation or growth inhibition by imatinib in mutant PDGFRA-driven cells. Imatinib Mesylate 129-137 platelet derived growth factor receptor, alpha polypeptide Mus musculus 30-36 15221957-8 2004 Ba/F3 cells expressing mutant PDGFRA are a good model to investigate the mechanism of cell proliferation or growth inhibition by imatinib in mutant PDGFRA-driven cells. Imatinib Mesylate 129-137 platelet derived growth factor receptor, alpha polypeptide Mus musculus 148-154 15009722-13 2004 Our data demonstrated that imatinib mesylate blocked both PDGFR-alpha and PDGFR-beta in vivo. Imatinib Mesylate 27-44 platelet derived growth factor receptor, alpha polypeptide Mus musculus 58-69 14695158-12 2003 Tumors from mice treated with both STI571 and gemcitabine had decreased expression of activated (phosphorylated) PDGFR-alpha and -beta, decreased mean vessel density, decreased cell proliferation, and increased apoptosis of tumor cells. Imatinib Mesylate 35-41 platelet derived growth factor receptor, alpha polypeptide Mus musculus 113-134 12781364-1 2003 FIP1L1-PDGFRalpha causes hypereosinophilic syndrome (HES) and is inhibited by the tyrosine kinase inhibitor imatinib (Gleevec). Imatinib Mesylate 108-116 platelet derived growth factor receptor, alpha polypeptide Mus musculus 7-17 12781364-1 2003 FIP1L1-PDGFRalpha causes hypereosinophilic syndrome (HES) and is inhibited by the tyrosine kinase inhibitor imatinib (Gleevec). Imatinib Mesylate 118-125 platelet derived growth factor receptor, alpha polypeptide Mus musculus 7-17 12781364-3 2003 However, we observed relapse with resistance to imatinib as consequence of a T674I mutation in FIP1L1-PDGFRalpha, analogous to the imatinib-resistant T315I mutation in BCR-ABL. Imatinib Mesylate 48-56 platelet derived growth factor receptor, alpha polypeptide Mus musculus 102-112 12781364-3 2003 However, we observed relapse with resistance to imatinib as consequence of a T674I mutation in FIP1L1-PDGFRalpha, analogous to the imatinib-resistant T315I mutation in BCR-ABL. Imatinib Mesylate 131-139 platelet derived growth factor receptor, alpha polypeptide Mus musculus 102-112 12949711-8 2003 Inhibitory effect of Imatinib mesylate on activated PDGFR alpha was examined. Imatinib Mesylate 21-38 platelet derived growth factor receptor, alpha polypeptide Mus musculus 52-63 12949711-12 2003 The constitutive activation of PDGFR alpha with Val-561 to Asp was inhibited effectively by Imatinib mesylate but that of PDGFR alpha with Asp-842 to Val was inhibited only weakly, even at the concentration of 10 micromol/L. Imatinib Mesylate 92-109 platelet derived growth factor receptor, alpha polypeptide Mus musculus 31-42 12808148-8 2003 Proliferation and viability of EOL-1 and BaF3 cells expressing Rhe-PDGFRalpha are ablated by the PDGFRalpha inhibitors imatinib, vatalanib, and THRX-165724. Imatinib Mesylate 119-127 platelet derived growth factor receptor, alpha polypeptide Mus musculus 67-77 12808148-8 2003 Proliferation and viability of EOL-1 and BaF3 cells expressing Rhe-PDGFRalpha are ablated by the PDGFRalpha inhibitors imatinib, vatalanib, and THRX-165724. Imatinib Mesylate 119-127 platelet derived growth factor receptor, alpha polypeptide Mus musculus 97-107 34247157-10 2021 Mechanistically, Gleevec, but not rapamycin, induced a significant elevation in caspase-3 activity in EPCs, and it attenuated the expression of the endothelial protein marker platelet-derived growth factor receptor alpha. Imatinib Mesylate 17-24 platelet derived growth factor receptor, alpha polypeptide Mus musculus 175-220 35528149-1 2022 Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR)-alpha, -beta, stem cell factor receptor (c-KIT), and BCR-ABL. Imatinib Mesylate 0-17 platelet derived growth factor receptor, alpha polypeptide Mus musculus 63-123 34027663-7 2021 Further, chrysin treatment reverses the effects of the specific PDGFRalpha inhibitor imatinib on browning differentiation of stromal vascular fraction cells from SAT. Imatinib Mesylate 85-93 platelet derived growth factor receptor, alpha polypeptide Mus musculus 64-74 35122213-10 2022 Finally, we show that treatment with a combination therapy that enhances endogenous fibrinolysis by inhibiting PAI-1 with MDI-2268 and reduces BBB permeability by inhibiting tPA-mediated PDGFRalpha signaling with imatinib significantly reduces infarct size compared to vehicle-treated mice and to mice with either treatment alone. Imatinib Mesylate 213-221 platelet derived growth factor receptor, alpha polypeptide Mus musculus 187-197 32590338-5 2020 In xenografts, imatinib therapy in BCPAP thyroid tumour-bearing mice significantly increased [18F]FDG uptake and retention (>30%) in BCPAP tumours with PDGFRbeta or both (alpha+beta) isoforms. Imatinib Mesylate 15-23 platelet derived growth factor receptor, alpha polypeptide Mus musculus 152-161 32944951-3 2020 Activating gain-of-function mutations in KIT and PDGFRA are the most frequent driver events, and most of these tumors are responsive to the tyrosine kinase inhibitor imatinib. Imatinib Mesylate 166-174 platelet derived growth factor receptor, alpha polypeptide Mus musculus 49-55 32597702-14 2020 The excessive arterial damage in the miR-223 knockout could be res-cued by adoptive transfer of platelet, administration of miR-223 mimics, or the PDGFRbeta inhibitor imatinib mesylate. Imatinib Mesylate 167-184 platelet derived growth factor receptor, alpha polypeptide Mus musculus 147-156